アブストラクト
| Title | IPMN診療ガイドライン2023における臨床症状の悪性予測因子としての位置付け |
|---|---|
| Subtitle | 特集 エビデンスに基づく膵IPMN国際診療ガイドライン改訂版 (Kyoto guidelines) のポイント |
| Authors | 竹中完1), 高島耕太1), 田中秀和1), 福永朋洋1), 吉田晃浩1), 山崎友祐1), 大本俊介1), 三長孝輔1), 鎌田研1), 工藤正俊1) |
| Authors (kana) | |
| Organization | 1)近畿大学消化器内科 |
| Journal | 胆と膵 |
| Volume | 45 |
| Number | 4 |
| Page | 385-390 |
| Year/Month | 2024 / 4 |
| Article | 報告 |
| Publisher | 医学図書出版 |
| Abstract | 「要約:」この度IPMN国際ガイドラインがInternational evidence-based Kyoto guidelines for the management of IPMN of the pancreasとして改訂された. 今回のもっとも大きな改訂は, 非切除IPMNのサーベイランスプロトコルの簡略化と, 5年間安定した経過をとっている分枝型IPMN(BD-IPMN)に対するサーベイランスを中止する可能性が提供されたことであるが, worrisome features(WF)に新たに過去1年以内の糖尿病の新規発症あるいは急性増悪が追加され臨床症状に重きを置いた改訂になっている. 本稿では, IPMNの悪性予測因子の中から, 「閉塞性黄疸」「膵炎」「糖尿病」といった"臨床症状"因子について概説する. |
| Practice | 臨床医学：内科系 |
| Keywords | IPMN国際ガイドライン2023, 京都ガイドライン |
- 全文ダウンロード： 従量制、基本料金制の方共に1,023円(税込) です。
参考文献
- 1) Tanaka M, Chari S, Adsay V, et al.: International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas. Pancreatology 6 : 17-32, 2006.
- 2) Tanaka M, Fernandez-del Castillo C, Adsay V, et al.: International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreatology 12 : 183-197, 2012.
- 3) Tanaka M, Fernandez-Del Castillo C, Kamisawa T, et al.: Revisions of international consensus Fukuoka guidelines for the management of IPMN of the pan-creas. Pancreatology 17 : 738-753, 2017.
- 4) Ohtsuka T, Fernandez-Del Castillo C, Furukawa T, et al.: International evidence-based Kyoto guidelines for the management of intraductal papillary muci-nous neoplasm of the pancreas. Pancreatology 24 : 255-270, 2024.
- 5) Attiyeh MA, Fernandez-Del Castillo C, Al Efishat M, et al.: Development and validation of a multi-institu-tional preoperative nomogram for predicting grade of dysplasia in intraductal papillary mucinous neo-plasms(IPMNs) of the pancreas : a report from the pancreatic surgery consortium. Ann Surg 267 : 157-163, 2018.
残りの17件を表示する
- 6) Heckler M, Brieger L, Heger U, et al.: Predictive performance of factors associated with malignancy in intraductal papillary mucinous neoplasia of the pan-creas. BJS Open 2 : 13-24, 2018.
- 7) Yamakawa K, Masuda A, Nakagawa T, et al.: Evalu-ation of efficacy of pancreatic juice cytology for risk classification according to international consensus guidelines in patients with intraductal papillary mucinous neoplasm : a retrospective study. Pancre-atology 19 : 424-428, 2019.
- 8) Uehara H, Abe Y, Kai Y, et al. : Predictors of malig-nancy in main duct intraductal papillary mucinous neoplasm of the pancreas. Gastrointest Endosc 95 : 291-296, 2022.
- 9) Ohtsuka T, Gotoh Y, Nakashima Y, et al.: Role of SpyGlass-DS(tm) in the preoperative assessment of pancreatic intraductal papillary mucinous neoplasm involving the main pancreatic duct. Pancreatology 18 : 566-571, 2018.
- 10) Talamini G, Zamboni G, Salvia R, et al.: Intraductal papillary mucinous neoplasms and chronic pancreati-tis. Pancreatology 6 : 626-634, 2006.
- 11) Ringold DA, Shroff P, Sikka SK, et al.: Pancreatitis is frequent among patients with side-branch intra-ductal papillary mucinous neoplasia diagnosed by EUS. Gastrointest Endosc 70 : 488-494, 2009.
- 12) Robles EP, Maire F, Cros J, et al.: Accuracy of 2012 International Consensus Guidelines for the prediction of malignancy of branch-duct intraductal papillary mucinous neoplasms of the pancreas. United Euro-pean Gastroenterol J 4 : 580-586, 2016.
- 13) Marchegiani G, Andrianello S, Perri G, et al.: The role of age in pancreatic intraductal papillary mucinous neoplasms of the pancreas : Same risk of death but different implications for management. Dig Liver Dis 50 : 1327-1333, 2018.
- 14) Kim S, Park BK, Seo JH, et al.: Carbohydrate antigen 19-9 elevation without evidence of malignant or pan-creatobiliary diseases. Sci Rep 10 : 8820, 2020.
- 15) Kim JR, Jang JY, Kang MJ, et al.: Clinical implication of serum carcinoembryonic antigen and carbohy-drate antigen 19-9 for the prediction of malignancy in intraductal papillary mucinous neoplasm of pan-creas. J Hepatobiliary Pancreat Sci 22 : 699-707, 2015.
- 16) Wang W, Zhang L, Chen L, et al.: Serum carcinoem-bryonic antigen and carbohydrate antigen 19-9 for prediction of malignancy and invasiveness in intra-ductal papillary mucinous neoplasms of the pan-creas : A meta-analysis. Biomed Rep 3 : 43-50, 2015.
- 17) Pergolini I, Schorn S, Jager C, et al.: Diabetes mellitus in intraductal papillary mucinous neoplasms : a sys-tematic review and meta-analysis. Surgery 169 : 411-418, 2021.
- 18) Morales-Oyarvide V, Mino-Kenudson M, Ferrone CR, et al.: Diabetes mellitus in intraductal papillary mucinous neoplasm of the pancreas is associated with high-grade dysplasia and invasive carcinoma. Pancreatology 17 : 920-926, 2017.
- 19) Jang DK, Ryu JK, Chung KH, et al.: Risk factors for progression or malignancy in main-duct and mixed-type intraductal papillary mucinous neoplasm of the pancreas. Pancreas 45 : 1027-1031, 2016.
- 20) Gausman V, Kandel P, Van Riet PA, et al.: Predictors of progression among low-risk intraductal papillary mucinous neoplasms in a multicenter surveillance cohort. Pancreas 47 : 471-476, 2018.
- 21) Duconseil P, Adham M, Sauvanet A, et al.: Fukuoka-negative branch-duct IPMNs : when to worry? A study from the French Surgical Association(AFC). Ann Surg Oncol 25 : 1017-1025, 2018.
- 22) Sofi AA, Ahmad S, Peerzada M, et al.: Diabetes mel-litus and the risk of progression or malignancy of pancreatic cystic neoplasms in patients undergoing surveillance : a systematic review and meta-analysis. Pancreatology 22 : 1195-1201, 2022.
